To the Editor:
Labile hemoglobin A 1c (Hb A 1c ), or pre-Hb A 1c , is an intermediate in the synthesis of Hb A 1c and is characterized by the reversible binding of glucose to Hb as a Schiff base (1 ) . Its biological variation is related to recent fluctuations in glycemia and cannot provide suitable retrospective information on a patient's long-term glycemic balance. Therefore, labile Hb A 1c must be eliminated from the measured Hb A 1c over the 6 -8 weeks before sampling in order to estimate the quality of diabetic control (2, 3 ) .
Most of the Hb A 1c methods available on the market either are insensitive to labile Hb A 1c (e.g., immunologic assays, affinity assays) or separate or even eliminate it during analysis (e.g., by HPLC or low-pressure liquid chromatography) (4 The presence of microalbuminuria in patients with diabetes mellitus (DM) 1 is associated with a 3-to 5-fold higher risk of cardiovascular mortality than in patients with DM without microalbuminuria and a risk of progression to end-stage kidney disease that is 10-fold higher. Predicting and/or preventing the development of albuminuria have substantial potential to improve outcomes and reduce costs in patients with DM.
Catalytic iron, also known as labile iron, consists of chemical forms that can participate in redox cycling. This property makes catalytic iron potentially hazardous because it can participate in the generation of powerful oxidant species, such as hydroxyl radicals and/or reactive iron-oxygen complexes such as the ferryl or perferryl ion (1, 2 ) . Animal models of glomerular disease exhibit increased urinary catalytic iron, and administration of an iron chelator reduces concentrations and protects against proteinuria (3 ). These findings suggest a pathogenetic role for catalytic iron. We postulated that the concentrations of catalytic iron may be higher in patients with DM, and if that is so, higher concentrations could precede the occurrence of proteinuria.
We conducted an ancillary study in a subgroup of 9 clinical centers (in 2 networks from the southeastern and western regions of the US) of the NIH-sponsored ACCORD (Action to Control Car-
